The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-South Africa, hit hard by coronavirus second wave, expects first vaccines Feb. 1

Wed, 27th Jan 2021 18:38

* South Africa worst affected country in Africa

* Fights more contagious virus variant

* AstraZeneca vaccine doses coming from India
(Adds ministry presentation, union reaction)

By Alexander Winning

JOHANNESBURG, Jan 27 (Reuters) - South Africa expects the
flight carrying its first 1 million coronavirus vaccine doses to
arrive on Feb. 1, Health Minister Zweli Mkhize said on
Wednesday, boosting efforts to curb a second wave of COVID-19
driven by a more contagious variant.

The AstraZeneca shots, produced by the Serum
Institute of India (SII), are destined for sorely stretched
healthcare workers.

South Africa has recorded the most coronavirus infections
and deaths on the African continent, at more than 1.4 million
cases and over 41,000 deaths to date. Since late last year, it
has been battling a more transmissible virus variant called
501Y.V2.

Mkhize said that after the 1 million doses arrive at the OR
Tambo international airport in Johannesburg they would be
subject to technical processes including quality assurance over
10 to 14 days.

They can then be distributed to all provinces, he added
during a public webinar. South Africa is due to receive a
further 500,000 doses from the SII in February, also for its
health workers.

Trade union NEHAWU said more doses needed to be secured
since the 1.5 million coming from the SII would only cover
750,000 health workers, as AstraZeneca's vaccine was
administered in two doses.

South Africa later stands to receive around 12 million doses
from the COVAX vaccine distribution scheme co-led by the World
Health Organization, another 12 million from an African Union
arrangement, and 9 million from Johnson & Johnson.

Mkhize spoke as South Africa's main opposition party, the
Democratic Alliance, began court action to force the government
to release details of its vaccination plans.

Some scientists and health workers have publicly criticised
the government for not securing doses sooner or outlining
detailed immunisation plans.

A health ministry presentation showed there were around 1.25
million health workers to be vaccinated, of which around 350,000
had insurance.

Vaccines would be delivered free at the point of service.
Medical schemes, funds that pool health insurance premiums,
would pay for those with insurance, with the government paying
for the uninsured.

Medicines regulator SAHPRA said earlier on Wednesday it had
given fast-track approval to AstraZeneca's vaccine for emergency
use and that it was reviewing data on the shots of rival
manufacturers Pfizer and J&J.

According to a National Treasury estimate, it could cost 20
billion to 24 billion rand ($1.3 billion to $1.6 billion) to
vaccinate the government's target of around 40 million people,
or two-thirds of the population.
(Reporting by Alexander Winning; additional reporting by
Mfuneko Toyana; Editing by Barbara Lewis, Mark Heinrich and
Grant McCool)

More News
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.